

# Supplementary Table 4

VALIDATION COHORT	TOTAL	LM	IM	HM	p
<b>PATIENTS</b>					
Patients	47	16	10	21	
<b>STUDY GROUP</b>					
EWOG-MDS	9 (19.1%)	2 (12.5%)	1 (10.0%)	6 (28.6%)	0.3326
JAPAN	18 (38.3%)	8 (50.0%)	5 (50.0%)	5 (23.8%)	0.1852
USA	20 (42.6%)	6 (37.5%)	4 (40.0%)	10 (47.6%)	0.8129
<b>DIAGNOSIS</b>					
JMML	46 (97.9%)	15 (93.8%)	10 (100.0%)	21 (100.0%)	
NS/MPD	1 (2.1%)	1 (6.2%)	0 (0.0%)	0 (0.0%)	
<b>AGE</b>					
Median (Range) [years]	1.7 (0.0, 6.4)	0.5 (0.0, 2.2)	1.0 (0.5, 2.7)	2.5 (1.7, 6.4)	<b>&lt;0.0001</b>
≥ 1 years	32 (68.1%)	5 (31.2%)	6 (60.0%)	21 (100.0%)	<b>&lt;0.0001</b>
≥ 2 years	20 (42.6%)	1 (6.2%)	1 (10.0%)	18 (85.7%)	<b>&lt;0.0001</b>
<b>SEX</b>					
Male	33 (70.2%)	11 (68.8%)	6 (60.0%)	16 (76.2%)	
Female	14 (29.8%)	5 (31.2%)	4 (40.0%)	5 (23.8%)	0.6460
<b>MUTATIONAL SUBGROUPS</b>					
PTPN11	20 (43.5%)	2 (13.3%)	4 (40.0%)	14 (66.7%)	<b>0.0061</b>
NF1	4 (8.7%)	0 (0.0%)	1 (10.0%)	3 (14.3%)	0.3204
NRAS	11 (23.9%)	6 (40.0%)	2 (20.0%)	3 (14.3%)	0.1933
KRAS	7 (15.2%)	3 (20.0%)	3 (30.0%)	1 (4.8%)	0.1542
CBL	2 (4.3%)	2 (13.3%)	0 (0.0%)	0 (0.0%)	0.1153
Quint.-neg.	2 (4.3%)	2 (13.3%)	0 (0.0%)	0 (0.0%)	0.1153
<b>KARYOTYPE</b>					
Monosomy 7	4 (8.7%)	0 (0.0%)	2 (20.0%)	2 (9.5%)	0.2169
<b>HbF</b>					
Elevated	35 (77.8%)	8 (57.1%)	6 (60.0%)	21 (100.0%)	<b>0.0036</b>
Normal	10 (22.2%)	6 (42.9%)	4 (40.0%)	0 (0.0%)	
n	45	14	10	21	
<b>LEUKOCYTES</b>					
Median (Range) [x10 <sup>9</sup> /L]	30.2 (5.0, 166.4)	25.4 (5.0, 166.4)	45.4 (13.5, 98.0)	28.9 (5.7, 132.6)	0.9135
≥ 25 x 10 <sup>9</sup> /L	31 (66.0%)	8 (50.0%)	9 (90.0%)	14 (66.7%)	0.1112
<b>PLATELETS</b>					
Median (Range) [x10 <sup>9</sup> /L]	67.0 (11.0, 490.0)	73.0 (26.0, 490.0)	66.0 (38.0, 302.0)	50.0 (11.0, 201.0)	0.0973
< 33 x 10 <sup>9</sup> /L	6 (12.8%)	2 (12.5%)	0 (0.0%)	4 (19.0%)	0.3315
< 50 x 10 <sup>9</sup> /L	14 (29.8%)	3 (18.8%)	2 (20.0%)	9 (42.9%)	0.2117
<b>SURVIVAL</b>					
Median OS [years]	6.7	NA	NA	2.27	<b>0.0031</b>
Median Follow-up (Range) [years]	2.3 (0.2, 10.8)	2.9 (0.2, 10.8)	1.5 (0.8, 3.4)	1.5 (0.2, 6.7)	